title: Lysozyme as a regulator of interleukin-2-activated lymphocyte proliferation.
abstract: Lysozyme at 1 to 100 micrograms/ml of exposure levels augmented or inhibited proliferative response of human peripheral blood lymphocytes stimulated with interleukin-2 (IL-2). This contradictory effect of lysozyme depended on IL-2 concentration, activating state of lymphocytes, addition time of lysozyme, and serum existence. Lymphocytes increased their IL-2-mediated proliferating ability in response to lysozyme when stimulated with less than suboptimal concentration of IL-2. Lymphocyte activation with anti-CD3 antibody changed the augmented proliferative response into the inhibited response by lysozyme addition whereas elimination of MHC class II molecule-expressing cells augmented the response. Addition of lysozyme within 1 h after IL-2 exposure was most effective in promoting the proliferation whereas additions after 16 to 24 h were ineffective or inhibitory. Addition after longer than 24 h inversely restored the proliferative response. Serum seemed to retard lysozyme action because either sequential serum addition 1 h after exposure of IL-2 and lysozyme to cells or exposure of IL-2 and serum after pretreatment of cells with lysozyme changed the proliferative responsiveness from inhibition into augmentation. Thus lysozyme may regulate lymphocyte proliferation responding to a magnitude of antigenic stimuli and to the progression of cellular events that periodically occur.
authors.affiliation: Department of Hygiene, Dokkyo University School of Medicine, Tochigi, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Yabe
authors.forename: K
authors.initials: K
authors.lastname: Komiya
authors.forename: T
authors.initials: T
authors.lastname: Takezono
authors.forename: H
authors.initials: H
authors.lastname: Matsui
mesh_terms: D017252:CD3 Complex / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D016895:Culture Media, Serum-Free; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000502:physiology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D009113:Muramidase / Q000502:physiology*; D010835:Phytohemagglutinins / Q000494:pharmacology
chemical_list: D017252:CD3 Complex; D016895:Culture Media, Serum-Free; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D010835:Phytohemagglutinins; D003208:Concanavalin A; D009113:Muramidase